|
|
  
Peer-reviewed publications on investigational products
DISCLAIMER: This information concerns a use that has not been approved or cleared by the FDA.
- Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63.
- Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Studies of the potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008; 52:4069-4071.
- Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol J-F, Glenn JS. The anti-hepatitis C agent nitazoxanide induces phosphorylation of elF2a via PKR activation. Gastroenterology 2009;137:1827-1835.
- Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008;28:574-580.
- Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in patients with chronic hepatitis C genotype 4 treated with nitazoxanide plus peginterferon alfa-2a with or without ribavirin. Gastroenterology 2009;136:856-862.
- Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol 2009;Epub before print.
- Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284:29798-29808.
|
 |
